Publication | Open Access

A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non–small cell lung cancer

OncologyPharmacologyPharmacotherapyAnti-cancer AgentCancer TreatmentLung CancerMedicineChemotherapy